In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
from Medical Xpress - latest medical and health news stories https://ift.tt/HjUi2yF
